Allison P. Nicklin

• Obsidian Therapeutics in its $160 million Series C financing
• Vittoria Biotherapeutics in its $25 million private financing
• N-Power Medicine in its Series B financing
• OraSure Technologies in connection with its investment in KKR Sapphiros, L.P.
• Represented a cell and gene therapy manufacturer in connection with its $350 million equity financing*
• Represented a regenerative medicine biotechnology company in connection with its $40 million preferred stock financing*
• Century Therapeutics, Inc. in connection with its restructuring and $160 million preferred stock financing*
• Represented multiple biotechnology startups in connection with sponsored research agreements, option and licensing agreements, and other collaborations with universities and academic institutions*

Allison also represents numerous other private companies and venture capital firms including Atlas Venture, Third Rock Ventures and others, in connection with their portfolio companies, debt and equity financings and related matters.

* Denotes experience prior to joining Goodwin

• Represented OraSure Technologies in the acquisition of Sherlock Biosciences
• Represented N-Power Medicine in the acquisition of Syapse Holdings, Inc.
• Represented FA212 in the sale of certain intellectual property assets to Solid Biosciences, Inc.
• Represented Tome Biosciences in the acquisition of Replace Therapeutics
• Represented a private equity-backed manufacturer of biomaterial coatings for medical devices in its strategic acquisition by a private equity fund*
• Represented a global pharmaceutical company focused on allergy diagnosis and treatment in the sale of its US veterinary business to a Swedish companion-animal allergy testing and treatment company*
• Represented a specialty pharmaceutical company focused on therapeutics for acute care settings in its spin-off from a public contract manufacturing organization and listing on the Nasdaq Capital Market*
• Represented a publicly traded international generic pharmaceutical company in the potential acquisition of a branded pharmaceutical company*
• Represented a global laboratory testing company in the acquisition of an analytical laboratory focused on environmental and agricultural testing*

* Denotes experience prior to joining Goodwin

• Represented a global pharmaceutical company in the license of a late-stage antibiotic for the treatment of complicated urinary tract infections; transaction includes up to $600 million in milestone payments*
• Represented a pharmaceutical company in connection with its license and collaboration with a neuroscience-focused, biopharmaceutical company in order to develop first-in-class treatments for epilepsy*
• Represented a biotechnology company in a licensing and collaboration agreement for two protein therapy platforms with a leader in RNA-targeting therapeutics*
• Represented biotechnology and pharmaceutical companies in connection with various research, development and collaboration agreements, license agreements, strategic funding transactions, and supply, commercialization and co-promote agreements*
• Represented a global pharmaceutical company in connection with multiple companion diagnostic development, manufacture and supply transactions*

* Denotes experience prior to joining Goodwin